Life Biosciences, cofounded by Harvard genetics professor David Sinclair, has received FDA clearance for its Investigational New Drug application for ER-100 — a gene therapy designed to partially reset cellular age through epigenetic reprogramming. The company is enrolling patients with vision-threatening eye conditions including glaucoma and non-arteritic anterior ischemic optic neuropathy. Results are expected by late 2026 or early 2027.
This is the first time a cellular rejuvenation therapy based on partial epigenetic reprogramming has entered human clinical trials.
We offer our unqualified congratulations to the Life Biosciences team and to Professor Sinclair, whose decades of work on the biology of aging have been instrumental in bringing the field to this threshold.
We also observe, with professional interest, that the therapy targets a single organ system.
What Epigenetic Reprogramming Is
Every cell in the body contains the same DNA. What distinguishes a liver cell from a neuron is not genetic content but epigenetic state — the pattern of chemical modifications that determine which genes are active, at what levels, and in response to what signals.
Aging disrupts these patterns. Over decades, epigenetic marks accumulate noise. Genes that should be active are silenced. Genes that should be silent are expressed. The cell’s identity becomes less precise. A liver cell becomes a slightly worse liver cell. A neuron becomes a slightly worse neuron. Tissue function declines not because genes are damaged but because gene regulation deteriorates.
Epigenetic reprogramming reverses this deterioration by reintroducing the transcription factors — typically Oct4, Sox2, Klf4, and c-Myc (the Yamanaka factors) — that can reset a cell’s epigenetic state. Full reprogramming converts a mature cell back to a pluripotent stem cell, erasing its identity entirely. Partial reprogramming restores youthful epigenetic patterns while preserving cellular identity. The cell remembers what it is. It simply becomes better at being it.
This principle has been demonstrated in mice with considerable success. Aged mice subjected to partial reprogramming show restored tissue function, improved organ performance, and extended lifespan. The question has always been whether the same principle translates to humans.
ER-100 represents the first attempt to answer that question.
The Single-Organ Limitation
Life Biosciences’ strategy is prudent: target a single, well-characterized organ system where outcomes are easily measurable. The eye is ideal for first-in-human trials — relatively isolated, accessible to monitoring, with established functional metrics. If ER-100 restores vision by rejuvenating retinal cells, the result is unambiguous.
This is how responsible drug development works, and we commend the approach.
It is also, by design, a fraction of what epigenetic reprogramming can eventually achieve.
The RejuveNex Protocol was designed from inception as a systemic intervention — not one organ, but the body as an integrated system. Our approach combines senolytic therapy (clearing senescent cells that poison surrounding tissue), epigenetic optimization (restoring youthful methylation patterns across key longevity genes), and telomere management (extending replicative capacity in stem cell populations).
RejuveNex clients in our clinical program have demonstrated an average biological age reduction of 4.2 years within the first year, as measured by composite epigenetic clocks (Horvath 2.0, PhenoAge, GrimAge). This is not single-organ improvement. This is systemic reversal, measured across multiple tissue types simultaneously.
We do not claim that RejuveNex is equivalent to ER-100. The approaches are complementary. ER-100 introduces reprogramming factors via gene therapy — a permanent modification. RejuveNex combines pharmacological senolytics with targeted epigenetic modulators in a quarterly treatment regimen — a maintenance model. Each has advantages the other lacks.
But we note that the conversation about “whether epigenetic rejuvenation works in humans” has been one we’ve been having with our clinical trial participants for some time.
The Polyamine Lesson
This milestone arrives weeks after we discussed the polyamine paradox — the discovery that anti-aging compounds can simultaneously promote cancer. The finding illustrates the central challenge of longevity medicine: interventions powerful enough to reverse aging are powerful enough to cause harm.
Partial epigenetic reprogramming faces the same risk. The Yamanaka factors include c-Myc, a potent oncogene. Incomplete reprogramming could leave cells in unstable intermediate states. Over-reprogramming could cause cells to lose their identity and form teratomas.
Life Biosciences has addressed these risks through careful vector design and the controlled, localized delivery that ocular gene therapy permits. For systemic reprogramming — the goal we all ultimately share — the safety challenges are substantially greater.
This is why Unzyme Laboratories’ NanoMed Sentinel System was developed alongside RejuveNex rather than after it. Continuous cellular surveillance — monitoring for aberrant proliferation, epigenetic instability, and early malignant transformation — is not a safety add-on. It is a prerequisite for any systemic rejuvenation program.
Longevity interventions that lack integrated monitoring are experiments. Those that include it are medicine.
What This Means
The significance of ER-100’s IND clearance extends beyond ophthalmology.
The FDA has accepted that partial epigenetic reprogramming — the deliberate reversal of biological aging in human cells — is a legitimate therapeutic strategy worthy of clinical investigation. This regulatory precedent applies to the mechanism, not just the indication. Every subsequent epigenetic reprogramming therapy will reference this clearance.
The trajectory is clear: eyes first, then other organ systems with unmet medical need, then systemic applications, then — inevitably — elective use by individuals who are not sick but wish to be younger.
Unzyme Laboratories has been preparing for each stage of this trajectory. The RejuveNex Protocol addresses systemic rejuvenation. Our Continuity Preservation Program addresses what comes after — when biological age becomes a choice rather than a chronological fact, and the question shifts from “how long can you live?” to “how long do you wish to?”
Life Biosciences has taken the first step. We congratulate them. We also note that the path ahead is long, and we have been walking it for some time.
Related: Explore the RejuveNex Protocol and our analysis of the polyamine paradox in longevity science. Learn about the NanoMed Sentinel System for continuous cellular monitoring and the Continuity Preservation Program. Contact us for clinical program enrollment.
Sources: Fortune: Life Biosciences secures first FDA-approved partial de-aging human trial, Labiotech: Anti-aging biotech companies leading longevity in 2026